ArticleAnnals of neurology2021
7T MRI Differentiates Remyelinated from Demyelinated Multiple Sclerosis Lesions.
Article in Annals of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Reliability of paramagnetic rim lesion classification on quantitative susceptibility mapping (QSM) in people with multiple sclerosis: Single-site experience and systematic review.Multiple sclerosis and related disorders · 2023Pooled it
- Fast and robust T1 mapping based on a 3D dual-echo UTE sequence (PETALUTE) for superparamagnetic iron oxide nanoparticle (SPION) biodistribution assessment.Medical physics · 2026Article
- TAnnals of clinical and translational neurology · 2026Article
- Field Strength-Dependent White Matter RMagnetic resonance in medicine · 2026Article
- A pipeline to characterize spinal cord pathology in neurological disorders combining magnetic resonance microscopy and histopathology.Communications medicine · 2026Article
- Ageing and remyelination failure in people with multiple sclerosis.Brain : a journal of neurology · 2026Review
- Motor tract lesion mapping from the brain to the lower spinal cord in people with relapsing-remitting multiple sclerosis: exploring the association between lesion severity and functional consequences by limb.Brain communications · 2026Article
- Quantitative T1 is sensitive to cortical remyelination in multiple sclerosis: A postmortem MRI study.Brain pathology (Zurich, Switzerland) · 2025Article
- Microstructural Damage and Repair in the Spinal Cord of Patients With Early Multiple Sclerosis and Association With Disability at 5 Years.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Article
- Sensitivity of multi-parametric quantitative magnetic resonance imaging for multiple sclerosis pathology.PloS one · 2025Article
- Clinical relevance of paramagnetic rim lesion heterogeneity in multiple sclerosis.Annals of clinical and translational neurology · 2024Article
- Imaging Outcomes for Phase 2 Trials Targeting Compartmentalized Inflammation.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Review
- Advanced MRI Measures of Myelin and Axon Volume Identify Repair in Multiple Sclerosis.Annals of neurology · 2024Article
- Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders.Signal transduction and targeted therapy · 2024Review
- Assessing disease progression and treatment response in progressive multiple sclerosis.Nature reviews. Neurology · 2024Review
- Imaging chronic active lesions in multiple sclerosis: a consensus statement.Brain : a journal of neurology · 2024Review
- Multiparametric Characterization and Spatial Distribution of Different MS Lesion Phenotypes.AJNR. American journal of neuroradiology · 2024Article
- New Imaging Markers in Multiple Sclerosis and Related Disorders: Smoldering Inflammation and the Central Vein Sign.Neuroimaging clinics of North America · 2024Review
- Quantitative TEuropean radiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo noninvasively assess myelin status in chronic white matter lesions of multiple sclerosis (MS), we developed and evaluated a simple classification scheme based on T1 relaxation time maps derived from 7-tesla postmortem and in vivo MRI.
methodsUsing the MP2RAGE MRI sequence, we classified 36 lesions from 4 postmortem MS brains as "long-T1," "short-T1," and "mixed-T1" by visual comparison to neocortex. Within these groups, we compared T1 times to histologically derived measures of myelin and axons. We performed similar analysis of 235 chronic lesions with known date of onset in 25 MS cases in vivo and in a validation cohort of 222 lesions from 66 MS cases, investigating associations with clinical and radiological outcomes.
resultsPostmortem, lesions classified qualitatively as long-T1, short-T1, and mixed-T1 corresponded to fully demyelinated, fully remyelinated, and mixed demyelinated/remyelinated lesions, respectively (p ≤ 0.001). Demyelination (rather than axon loss) dominantly contributed to initial T1 prolongation. We observed lesions with similar characteristics in vivo, allowing manual classification with substantial interrater and excellent intrarater reliability. Short-T1 lesions were most common in the deep white matter, whereas long-T1 and mixed-T1 lesions were prevalent in the juxtacortical and periventricular white matter (p = 0.02) and were much more likely to have paramagnetic rims suggesting chronic inflammation (p < 0.001). Older age at the time of lesion formation portended less remyelination (p = 0.007).
interpretation7-tesla T1 mapping with MP2RAGE, a clinically available MRI method, allows qualitative and quantitative classification of chronic MS lesions according to myelin content, rendering straightforward the tracking of lesional myelination changes over time. ANN NEUROL 2021;90:612-626.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.